Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTED.L Regulatory News (TED)

  • There is currently no data for TED

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - TED BAKER PLC

11 Oct 2022 14:15

RNS Number : 5272C
Barclays PLC
11 October 2022
 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

 

Barclays PLC.

(b)

Owner or controller of interest and short

 

 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

TED BAKER PLC

 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

 

 

offeror/offeree, state this and specify identity of

 

offeror/offeree:

(e)

Date position held/dealing undertaken:

10 Oct 2022

(f)

In addition to the company in 1(c) above, is the discloser making

NO

 

 

 

disclosures in respect of any other party to the offer?

 

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

 

 

to which the disclosure relates following the dealing(if any)

 

Class of relevant security:

5p ordinary

 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

and/or controlled:

 

 

8,192,829

4.44%

729,460

0.40%

(2)

Cash-settled derivatives:

 

 

 

 

 

and/or controlled:

 

 

273,360

0.15%

7,552,371

4.09%

(3)

Stock-settled derivatives (including options)

 

 

 

 

 

and agreements to purchase/sell:

 

 

0

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

TOTAL:

 

 

8,466,189

4.59%

8,281,831

4.49%

(b)

Rights to subscribe for new securities (including directors and other executive

 

 

options)

 

 

 

 

 

 

Class of relevant security in relation to

 

 

 

 

which subscription right exists

 

 

 

 

Details, including nature of the rights

 

 

 

 

concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

 

 

 

 

 

Class of relevant

Purchase/sale

Number of

Price per unit

security

 

securities

 

5p ordinary

Purchase

3,816

1.0959 GBP

5p ordinary

Purchase

53,801

1.0960 GBP

5p ordinary

Purchase

115,358

1.0980 GBP

5p ordinary

Sale

133,087

1.0960 GBP

 

 

 

 

 

 

 

 

(b)

Cash-settled derivative transactions

 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

 

reference

unit

security

 

 

securities

 

5p ordinary

SWAP

Long

14,742

1.0959 GBP

5p ordinary

SWAP

Long

121,831

1.0960 GBP

5p ordinary

SWAP

Short

2,409

1.0969 GBP

5p ordinary

CFD

Short

23,942

1.0960 GBP

5p ordinary

SWAP

Short

54,202

1.0980 GBP

5p ordinary

CFD

Short

61,156

1.0981 GBP

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

 

date

money

relevant

 

selling,

securities

per unit

 

 

paid/

security

 

varying etc

to which

 

 

 

received

 

 

 

option

 

 

 

per unit

 

 

 

relates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii)

Exercising

 

 

 

 

 

 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

 

 

securities

unit

 

 

 

 

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

 

 

applicable)

 

 

 

 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding,

 

 

formal or informal, relating to relevant securities which may be an inducement to deal

 

 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

 

to the offer or any person acting in concert with a party to the offer:

 

 

 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between

 

 

the person making the disclosure and any other person relating to:

 

 

(i) the voting rights of any relevant securities under any option; or

 

 

 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

 

 

any derivative is referenced:

 

 

 

 

 

 

NONE

(c)

Attachments

 

 

 

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

11 Oct 2022

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETBXBDGSBBDGDB
Date   Source Headline
18th Mar 20228:20 amRNSDirector/PDMR Shareholding
18th Mar 20227:00 amRNSStatement re Possible Offer
7th Mar 20221:01 pmRNSHolding(s) in Company
23rd Feb 20227:00 amRNSQ4 2022 / Pre-close trading update
17th Dec 20213:04 pmRNSBoard composition
6th Dec 20217:00 amRNSJohn Barton
1st Dec 20214:56 pmRNSTotal Voting Rights
11th Nov 202110:48 amRNSReplacement Interim Results
11th Nov 20217:00 amRNSInterim Results
5th Nov 202112:04 pmRNSDirectorate Change
2nd Nov 20213:13 pmRNSBlock listing Interim Review
6th Oct 20214:17 pmRNSDirector/PDMR Shareholding
4th Oct 20217:00 amRNSNew Joint Broker
7th Sep 20217:00 amRNSQ2 Trading Update
4th Aug 20217:00 amRNSDirectorate Change
3rd Aug 202111:22 amRNSDirector/PDMR Shareholding
28th Jul 20213:12 pmRNSNotice of Results
28th Jul 20217:00 amRNSNotice of Q2 Trading Update
23rd Jul 20217:00 amRNSNew Global HQ
28th Jun 20217:00 amRNSNotice of AGM
17th Jun 20217:00 amRNSHolding(s) in Company
14th Jun 20217:00 amRNSFinal Results
9th Jun 20213:11 pmRNSChange to Full Year Results Date
25th May 20217:00 amRNSSuccessful bank refinancing
24th May 20217:00 amRNSChange to Full Year Results Date
13th May 20217:00 amRNSHolding(s) in Company
6th May 20212:54 pmRNSBlock listing Interim Review
29th Apr 202110:55 amRNSHolding(s) in Company
11th Mar 20217:00 amRNSTed Baker announces new territory licence deals
24th Feb 202112:30 pmRNSAdditional Listing
11th Feb 20217:00 amRNSNotice of Results
4th Feb 202110:01 amRNSTotal Voting Rights
8th Jan 20213:47 pmRNSNotice of Results
16th Dec 20206:35 pmRNSDirector/PDMR Shareholding
7th Dec 20207:00 amRNSInterim Results
10th Nov 20207:00 amRNSChange to Interim Results Date
3rd Nov 20205:07 pmRNSBlock listing Interim Review
2nd Nov 202011:49 amRNSHolding(s) in Company
26th Oct 202010:50 amRNSDirector/PDMR Shareholding
14th Oct 202011:31 amRNSNotice of Results
7th Oct 20204:56 pmRNSHolding(s) in Company
6th Oct 20202:34 pmRNSTotal Voting Rights
30th Sep 202010:17 amRNSDirector/PDMR Shareholding
4th Sep 20202:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20204:26 pmRNSDirector/PDMR Shareholding
1st Sep 202010:10 amRNSDirectorate Change
18th Aug 20205:13 pmRNSDirector/PDMR Shareholding
4th Aug 202011:58 amRNSTotal Voting Rights
24th Jul 20205:54 pmRNSHolding(s) in Company
21st Jul 202012:17 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.